Physician profile
Abraham Flemenbaum
NPI 1174613194
$2,393.96
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,871 · 2020: $523.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $608.76 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $307.82 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $290.82 | 2019-2020 | |
| Lundbeck LLC | $245.93 | 2019-2020 | |
| Bausch Health US, LLC | $202.28 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $189.07 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $159.49 | 2019-2020 | |
| Shire North American Group INC | $112.38 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $78.85 | 2019 | |
| Janssen Pharmaceuticals, INC | $46.30 | 2019 | |
| Ironshore Pharmaceuticals INC. | $41.16 | 2019 | |
| Neuronetics, INC. | $21.76 | 2019 | |
| Eisai INC. | $20.77 | 2020 | |
| Noven Therapeutics, LLC | $19.59 | 2020 | |
| Jazz Pharmaceuticals INC. | $17.51 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $15.87 | 2019 | |
| Arbor Pharmaceuticals, INC. | $15.60 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abraham Flemenbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.